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ABSTRACT 
According to the triple network hypothesis the brain is equipped with three core neurocognitive 
networks: the default mode (DMN), the salience (SN), and the central executive (CEN) network. 
Moreover, the so called dorsal nexus, has met growing interest as it is a hub region connecting 
these three networks. Assessment of resting-state functional connectivity (rsFC) of these 
networks enables the elucidation of drug-induced brain alterations. Gamma-hydroxybutyrate 
(GHB) is a GHB/GABA-B receptor agonist that induces a paradoxical state of mixed stimulation 
and sedation at moderate doses, which makes it a valuable tool to investigate neural signatures 
of subjective drug effects. Employing a placebo-controlled, double-blind, randomized, cross-over 
design, we assessed the effects of GHB (35 mg/kg p.o.) in 19 healthy male subjects on DMN-, 
SN-, CEN-, and dorsal nexus-rsFC measured by functional magnet resonance imaging and 
applying independent component as well as seed-based analyses, while subjective drug effects 
were investigated using visual analog scales (VAS). Subjectively, GHB increased VAS ratings of 
a general drug effect, stimulation, and sedation. Intrinsic DMN-, and CEN-rsFC remained largely 
unchanged under GHB, but the drug increased SN-DMN-rsFC and SN-dorsal nexus-rsFC, while 
dorsal nexus-rsFC was reciprocally increased to both the SN (right anterior insula) and to the 
CEN (right middle frontal gyrus [MFG]). Increased sedation significantly predicted the observed 
SN-dorsal nexus-rsFC. In conclusion, GHB generates a unique stimulant/sedative subjective 
state that is paralleled by a complex pattern of increased functional connectivity encompassing 
all three core neurocognitive networks of the brain, while increased SN-dorsal nexus-rsFC was 
demonstrated to be a potential signature of the sedative component of the drug effect. 
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1. INTRODUCTION  
The understanding of the relationship between brain activity and subjective experience, including 
their coordinated manipulation by pharmacological interventions, is fundamental for the 
identification of brain function and the development of innovative treatment of psychiatric 
conditions. A valid method to investigate such drug-induced functional brain alterations is 
pharmaco-functional magnetic resonance imaging (fMRI) measuring blood oxygenation level-
dependent (BOLD) signals. Specifically, resting-state functional connectivity (rsFC) can reveal 
brain signatures of pharmacological compounds and relationships between brain network activity 
patterns and subjective phenomena (Salmeron and Stein, 2002). The so-called triple network 
model unifies the three core neurocognitive large-scale brain networks, the default mode 
network (DMN), the salience network (SN), and the central executive network (CEN), providing a 
better understanding of brain function and dysfunction (Menon, 2011). The DMN shows the 
strongest BOLD activity during rest (Buckner et al., 2008), comprises cortical midline structures 
such as the precuneus and medial frontal cortex as well as the inferior parietal lobule (Fox and 
Raichle, 2007, Raichle et al., 2001), and is involved in the recollection of prior experiences, 
emotional processing, and other self-referential mental activities (Raichle, 2015). The posterior 
cingulate cortex (PCC) is commonly considered as the central node of the DMN (Khalsa et al., 
2014). The SN is active both during rest and during task-related activity and is understood as 
network with a switching function between the DMN and the CEN, identifying biologically and 
cognitively relevant stimuli to guide adaptive behavior (Menon, 2015). It is anchored in the 
anterior insula and the dorsal part of the anterior cingulate cortex (ACC), but also includes 
subcortical structures such as the amygdala, the ventral striatum/ nucleus accumbens Nacc 
(Nacc), and the ventral tegmental area (VTA) (Craig, 2009, Gogolla et al., 2014, Menon and 
Uddin, 2010). Finally, the CEN is anchored in the dorsolateral prefrontal cortex and lateral 
posterior parietal cortex and is mainly active during task-related cognitive control activity 
involving working memory, problem solving, and decision making or other goal-directed behavior 
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(Koechlin and Summerfield, 2007, Niendam et al., 2012, Seeley et al., 2007). The CEN in the 
here used definition overlaps or is part of previously described networks such as the fronto-
parietal network (Smith et al., 2009, Spreng et al., 2013, van den Heuvel et al., 2009), referring 
to its anatomical location, and attention network (Markett et al., 2014, Toro et al., 2008), focusing 
on a functional aspect. Intriguingly, a connectivity hub in the dorsomedial prefrontal cortex 
(dmPFC), the so-called dorsal nexus, was discovered to serve as an interface between the 
DMN, SN, and CEN in depressed patients (Sheline et al., 2010). It was postulated that dorsal 
nexus-rsFC alterations may serve as biomarkers for antidepressant effects, which was 
supported by studies using antidepressant interventions including citalopram (McCabe et al., 
2011), ketamine (Scheidegger et al., 2012), and sleep deprivation (Bosch et al., 2013).  
Gamma-hydroxybutyrate (GHB), a mixed GABA-B (Engberg and Nissbrandt, 1993) and GHB 
receptor (Benavides et al., 1982) agonist, is an interesting neuropsychopharmacological 
research tool as it exerts a paradoxical state of mixed stimulation and sedation, among other 
more specific drug effects. In humans, GHB strongly influences behaviors related to core human 
autonomic functions such as control of food intake, sexual behavior, and sleep-wake regulation 
(Bosch and Seifritz, 2016). Moreover, the drug was shown to exert prosocial (Bosch et al., 2015, 
Sumnall et al., 2008) and prosexual effects (Kapitany-Foveny et al., 2015), latter of which are 
associated with increased activity in the ACC and Nacc (Bosch et al., 2017b). Moreover, GHB 
increases regional cerebral blood flow (rCBF) in the right anterior insula and bilateral ACC, 
which was correlated with increased body and emotion awareness (Bosch et al., 2017a). On a 
subjective level, GHB induces a mixed stimulant-sedative pattern, including stimulation, 
sedation, euphoria, disinhibition, and enhanced vitality (Bosch et al., 2015). Thus, GHB shares 
properties usually attributed to both sedatives such as benzodiazepines, z-drugs, or alcohol, as 
well as stimulants such as methylphenidate, amphetamines, or cocaine (Bosch and Seifritz, 
2016). This specific pharmacological profile is clinically utilized in neuropsychiatric disorders 
such as narcolepsy, alcohol withdrawal, fibromyalgia, and binge-eating syndrome. Additionally, 
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the subjective, prosocial and prosexual effects are instrumentalized by non-medical users 
(Teltzrow and Bosch, 2012). Taken together, these properties led to the suggestion that GHB 
might be an interesting experimental antidepressant agent (Bosch et al., 2012, Mamelak, 2009).  
Functional brain signatures of sedative and stimulant drugs have been described using rsFC, but 
the effects of GHB are unknown yet. As GHB primarily acts agonistically on GABA 
neurotransmission and has strong secondary effects on the dopamine system (Bosch and 
Seifritz, 2016), it is conceivable that GHB produces rsFC alterations as seen after GABA- and/or 
dopaminergic drug administration. Sedative GABAergic drugs such as zolpidem (Licata et al., 
2013), midazolam (Greicius et al., 2008, Kiviniemi et al., 2005, Liang et al., 2015), and alcohol 
(Esposito et al., 2010, Khalili-Mahani et al., 2012) were consistently found to increase rsFC with 
and within the SN and/or CEN, while simultaneously reducing intrinsic DMN-rsFC. By contrast, 
the findings on the effect of stimulants on rsFC appear to be more inconsistent. RsFC reductions 
were found for cocaine within the primary visual and motor cortices (Li et al., 2000), for 
dexamphetamine within DMN, SN, and CEN (Schrantee et al., 2016), for methylphenidate in the 
thalamus, the supplementary motor area (Konova et al., 2015), and the mesolimbic reward 
system (Ramaekers et al., 2013). On the other hand, mixed patterns of rsFC increase and 
reduction were found for methylphenidate encompassing motor and limbic (Farr et al., 2014, 
Kline et al., 2016, Mueller et al., 2014), as well as DMN, SN, and CEN nodes (Sripada et al., 
2013). Moreover, the stimulant modafinil, which is like GHB clinically used for narcolepsy 
treatment, increased rsFC between the insula and the putamen, the superior frontal gyrus, and 
the ACC (Cera et al., 2014), and of the left CEN to the pre-supplementary motor area (preSMA), 
the occipital pole, and the inferior parietal gyrus (Esposito et al., 2013) in healthy subjects. 
Unfortunately, no information was given regarding putative correlations between subjective and 
neural data in any of these previous studies.  
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To identify GHB-specific functional brain alterations and their possible relationships to putative 
subjective drug-effects, we assessed rsFC at baseline and + 34 min, + 59 min, and + 79 min 
post challenge with 35 mg/kg p.o. vs. placebo in healthy male subjects. Visual analog scales 
(VAS) were used to measure subjective feelings of the general drug effect, stimulation, and 
sedation. We hypothesized that GHB increases subjective sedation and stimulation, which 
correlates with rsFC alterations of the DMN, SN, CEN, and the dorsal nexus.  
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2. MATERIAL AND METHODS 
2.1 Design and Study Subjects 
A randomized, double-blind, placebo-controlled, balanced, crossed within-subject design was 
used. All subjects were non-smoking, healthy males. Nineteen subjects with a mean age of 23.5 
years (standard deviation: ±3.6, range: 20-36), a mean verbal intelligence quotient (IQ) of 113.4 
(±18.4, 88-145), and a mean weight of 72.2 kg (±7.4, 59-85) participated. Subjects were 
recruited by online advertisings and underwent a medical and psychiatric examination applying 
the Structured Clinical Interview for DSM-IV Axis-I Disorders (First et al., 2002). Exclusion 
criteria were any DSM-IV psychiatric disorder, neurological disorder, severe medical disease, 
left-handedness, and regular illegal drug use (lifetime use >5 occasions, with exception of 
occasional cannabis use), latter assessed by using the Interview for Psychotropic Drug 
Consumption (Quednow et al., 2004). Subjects performed a German vocabulary test, the 
Mehrfachwahl-Wortschatz-Intelligenztest (Lehrl, 2005), to estimate the verbal IQ. They had to 
abstain from drinking alcohol 24 h before the experimental sessions and from drinking 
caffeinated beverages during the course of the study days. Abstinence from illegal drugs at the 
test sessions was ensured by semi-quantitative drug urine tests (Dimension RXL Max, Siemens, 
Erlangen, Germany). The study was approved by the Cantonal Ethics Committee of Zurich and 
by Swissmedic and registered at ClinicalTrials.gov (NCT02342366). All subjects gave written 
informed consent and were financially compensated. 
 
2.2 Procedure 
GHB and placebo were applied in two order-balanced sessions separated by seven days. On 
both test days, subjects completed an fMRI paradigm (Bosch et al., 2017b) on a Philips Achieva 
3T whole-body MR-unit equipped with a 32-channel head coil (Philips Medical Systems, Best, 
The Netherlands). The experiment started with a T1-weighted anatomical brain scan, a baseline 
rsFC (, all 6 min duration), and an arterial spin labeling (ASL, all 5 min duration) scan. 
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Subsequently, subjects were taken out of the scanner and were orally administered with a single 
dose of GHB (35 mg/kg) or placebo (t=0 min) (order-balanced). As Cmax of GHB can be expected 
after about 40 min (Liechti et al., 2016), the fMRI challenge session began at t +30 min followed 
by a challenge rsFC (+34 min) and an ASL (+40 min) scan. Thereafter, subjects underwent the 
first run of the fMRI paradigm (a visual stimulation task, t=+48 min). After that, another rsFC 
(+59 min) and subsequent ASL (+65 min) scan was performed which was followed by the 
second run of the fMRI paradigm (t=+ 70 min). At the end of the experiment, final rsFC (+79 min) 
and ASL (t=+ 85 min) scans were acquired again after which subjects were taken out of the 
scanner and debriefed. Subjective drug effects were measured using computerized VAS 
(100mm scale, with item name and according statement, e.g. ‘I feel a drug effect’ for general 
drug effect, with ‘not at all’ and ‘strongly’ on the poles of the scale, selection via hand tool with 
scroll function) assessing general drug effect, sedation, relaxation, stimulation, euphoria, body 
awareness, emotion awareness, sexual arousal, dizziness, and nausea at time points t=-25 min 
before and +45 min, +55 min, +68 min, +77 min, and +93 min after drug/placebo administration 
in the scanner but not during scans (see supplementary figures 1 and 2) (Abanades et al., 
2006, Bosch et al., 2015, Thai et al., 2007). Experimental sessions lasted 200 min. Here, the 
GHB effects on VAS items general drug effect, sedation, and stimulation and rsFC data are 
presented, while the ASL and task-related fMRI data were published elsewhere (Bosch et al., 
2017a, Bosch et al., 2017b). 
 
2.3 MRI Data Acquisition 
rsFC time series were acquired with a sensitivity-encoded single-shot echo-planar imaging 
sequence (SENSE-sshEPI) (45). The rsFC protocol used the following acquisition parameters: 
TE=35ms, TR=2000ms, flip angle=82°, FOV=22cm2, acquisition matrix=80x80 (in plane voxel 
size=2.75x2.75mm2), 32 contiguous axial slices (placed along the anterior-posterior commissure 
plane) with a slice thickness of 4mm, and a SENSE factor R=2.0. For structural reference, a 
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magnetization prepared rapid gradient-echo (MP-RAGE) T1-weighted anatomical scan was 
acquired with the following parameters: TR/TE=9.3/4.6ms, flip angle=8°, 160 sagittal slices, FOV 
240×240 mm, voxel size=1×1×1mm. 
 
2.4 MRI Data Preprocessing 
Standard image data preparation and pre-processing, as well as statistical analysis and 
visualization were performed with the software BrainVoyager QX (Brain Innovation BV, The 
Netherlands). Functional data preprocessing included a correction for slice scan timing 
acquisition, a 3D rigid body motion correction, a spatial smoothing (gaussian kernel of 6 mm full-
width-half-maximum), a temporal high-pass filter with cut-off set to 0.0080 Hz per time-course 
and a temporal low-pass filter (gaussian kernel of 3 s). After 3D rigid body correction, a 24-
parameter model of head motion was created for each data set with the purpose of regressing 
out any residual effects of motion from each data set prior to functional connectivity estimation. 
This model incorporates the 6 head motion translation and rotation parameters estimated during 
3D rigid body correction, the 6 first order derivatives of the motion parameters, and the 12 
corresponding squared items (Friston et al., 1996, Satterthwaite et al., 2013).   
Structural and functional data were co-registered and spatially normalized to the Talairach 
standard space using a twelve parameter affine transformation. In the course of this procedure, 
the functional images were resampled to an isometric 3x3x3 mm3 grid covering the entire 
Talairach box. Nuisance physiological signals from white matter (WM) and cerebro-spinal fluid 
(CSF) were estimated from each data set by segmenting the WM and the ventricles in the 
normalized T1 volumes and calculating the average WM and CSF signals from these volumes. 
Following previous recommendations (Geerligs et al., 2017, Shirer et al., 2015, Varikuti et al., 
2017), all 24 motion parameters, together with the WM and CSF signals, were regressed out 
from each time-course at each voxel. 
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2.5 Statistical Analysis of VAS Data 
For the analyses of VAS scales, repeated measures analysis of variance (ANOVA) with drug (2-
fold: GHB, placebo) and time (6-fold) as within-subject factors and session (GHB-first vs. 
placebo-first) as between-subject factor were applied using SPSS®22.0 for Windows. 
Bonferroni-corrected paired t-tests were applied for post hoc treatment comparisons (placebo vs. 
GHB). All confirmatory statistical comparisons were carried out at a significance level of p<.05 
(two-tailed). 
 
2.6 Statistical Analysis of MR Images 
2.6.1. Independent Component Analysis of Resting-state fMRI Networks 
A hierarchical independent component analysis (ICA) approach was performed to study the 
functional connectivity of resting-state networks (RSNs) under changing experimental conditions 
similar to previous studies (see, e. g., (Esposito et al., 2014)). First-level (single-subject, single-
scan) and second-level (group) ICA analyses were performed on the pre-processed functional 
time series using two plug-in extensions of BrainVoyager QX, respectively implementing the so-
called fastICA algorithm (Hyvarinen, 1999) and the self-organizing group-level ICA (sogICA) 
algorithm (Esposito et al., 2005). 
For each subject and each scan, 30 independent components were extracted using fastICA, 
roughly corresponding to 1/6 of the number of time points (see, e. g. (Greicius et al., 2007, 
Shirer et al., 2015). Minimum description length (MDL) (Rissanen, 1978), as implemented in FSL 
MELODIC command line program (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/MELODIC), was also used 
to analytically justify the number of components extracted from each data set.  
All 30 ICA component maps from the baseline scans of the first experimental session (n=18) 
were “clustered” at the group level using the sogICA algorithm (Esposito et al., 2005), yielding 30 
12 
 
group ICA component t-statistic maps as follows. The 30 clusters of 18 components (one per 
subject) were entered into a 1-factor random-effect ANOVA with 1 within-subject factor (cluster 
membership) with 30 levels (one per component) and subjects as random observations. From 
this 1-way ANOVA, we produced 1-sample t-test maps (one for each cluster) and extracted the 
components lay-out (mask) by applying a voxel-level threshold of p=0.05 (Bonferroni corrected 
for multiple voxel-level comparisons). To identify (and label) an interested network, the 
component mask was preliminary applied to ten external well-matched ICA components 
available on line (http://www.fmrib.ox.ac.uk/datasets/brainmap+rsns/) (Smith et al., 2009). The 
best matching between a group ICA component map and an RSN component map resulted from 
the highest average ICA score inside the mask. The selected (and matched) group ICA 
component masks were thus used to create (treatment-independent) internal templates for 
DMN, SN, left and right CEN, and VN, and used to select the individual ICA components from 
each individual scan (baseline, challenge [+ 34 min], + 59 min, + 79 min). Each internal RSN 
template mask was used to select one best-fitting RSN component per subject and per scan for 
the second-level random-effects statistical analysis (see 2.6.3). The best-fitting RSN component 
was the component reporting the highest goodness-of-fit score, defined as the difference 
between the average component score inside the mask minus the average component score 
outside the mask (Esposito and Goebel, 2011, Greicius et al., 2004). 
For each RSN of interest, all selected ICA component maps were entered into the second-level 
(group-level) statistical analysis (see paragraph 2.6.3). Importantly, these were all native ICA 
components, i.e. ICA maps (and time-courses) directly estimated from the fastICA algorithm 
applied to each data set, and were not the result of a matrix back-projection or dual (spatio-
temporal) regression from groups of ICA components back to individual data sets. The 
difference between the two types of group-level ICA approaches (individual vs. aggregate) has 
been previously reviewed and discussed by (Esposito and Goebel, 2011). 
13 
 
Besides the within-network connectivity changes within a given RSN of interest (see 2.6.3), the 
between-network connectivity changes (between two RSNs) were also assessed from the ICA 
component time-courses. Thus, the scan- and subject-specific ICA component time-courses 
were extracted for all individual ICA components selected as SN, DMN, R- and L-CEN and 
correlation coefficients (Pearson’s r) were computed per scan per subject for all possible pairs of 
ICA component time-courses for each individual scan. The resulting connectivity matrix was 
used for a second-level (group-level) statistical analysis after Fisher transformation from r to z 
values. Thereby, paired t-tests were conducted to compare correlation z values between the SN 
and DMN, the SN, the CENs and between the DMN and the CENs across different experimental 
conditions (GHB vs. placebo at challenge [+ 34 min] and challenge vs. baseline for GHB and 
placebo sessions). Mean connectivity regression of the within-subject connectivity matrices 
(Geerligs et al., 2017, Yan et al., 2013) was also performed, albeit without pre-whitening due to 
the choice of low-pass filtering the original time-courses. Bonferroni correction was applied to the 
p-values to correct for the multiple tests (over all inter-network connectivities and all 
experimental conditions). 
 
2.6.2 Seed-based Functional Connectivity Analysis 
A seed-based analysis was performed to study the functional connectivity from the PCC and 
dorsal nexus to the entire brain identically to previous studies (Bosch et al., 2013, Scheidegger 
et al., 2012). These seeds were selected as the PCC is commonly considered as the central 
node of the DMN (Khalsa et al., 2014), while the dorsal nexus seed was discovered to be a 
candidate biomarker for an antidepressant treatment response (Sheline et al., 2010), which was 
further investigated in previous studies of ours (Bosch et al., 2013, Scheidegger et al., 2012). To 
compute functional connectivity maps corresponding to a selected seed region of interest (ROI), 
the mean regional time-course was extracted from all ROI voxels and correlated against all 
voxels of the brain. The (rationale for) definition of these two ROIs was identical to the previous 
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works (see (Bosch et al., 2013, Scheidegger et al., 2012) for all details). Separate correlation 
maps were produced for each subject, condition, and ROI. The correlation maps were applied 
the Fisher’s r-to-z transform z=0.5 Ln [(1+r)/(1−r)] before entering the second-level random-
effects statistical analysis (see paragraph 2.6.3). 
Because seed-based connectivity estimates can be affected by micro-movements (Power et al., 
2012), a supplementary motion analysis was performed to control for possible effects of residual 
motion artifacts in the data. Following Power et al. (2012), the frame wise displacement (FD) 
was calculated for each time point of each scan using the motion estimates obtained at the 
preprocessing stage. Then, prior to nuisance regression, volume censoring was applied to all 
volumes exhibiting an FD above 0.2 mm as well as to the two volumes preceding and following 
such volumes in the time-series (Power et al., 2015). For the second-level (group-level) 
analyses, the mean FD was considered as a covariate of no interest and regressed out from the 
series of z-values (across subjects) to remove any further residual effects of motion from the 
second-level analysis. 
 
2.6.3 Group-level Analysis of Functional Connectivity Maps 
For the whole-brain voxel-based rsFC analysis, all Talairach-normalized functional connectivity 
z-maps (either ICA z-maps for each network of interest or seed-based correlation z-maps) from 
all 144 rsFC data sets (18 subjects, 2 session, 4 repeated scans) were combined and entered 
into the analysis of covariance module of BrainVoyager QX. Here, a 3-way (4x2x2) mixed-effects 
ANOVA design was specified with two within-subject factors (scan, treatment), and one 
between-subject factor (session). Following the experimental design, the factor scan was 
assigned with four levels (baseline, t=+34 min, t=+59 min, t=+79 min), the factor treatment with 
two levels (GHB, placebo) and the factor session with two levels (GHB-first, placebo-first). All 
interactions between and among all three factors were also added to the model. The session 
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factor was a between-subject factor because half of the subjects had the GHB session as first 
session (and the placebo session as second session) and half of the subjects had the GHB 
session as second session (and the placebo session as second session). This introduced a 
potential session effect (GHB-first vs. placebo-first) that was accounted for as a between-subject 
factor. 
After least square model fitting, to detect any effects of systematic functional connectivity 
changes in relation to time, treatment and session, the t statistics for the contrast [GHB 
(challenge [+ 34 min]) - GHB (baseline)] vs. [placebo (challenge) - placebo (baseline)] was 
computed at each voxel, yielding a whole-brain t-statistic map, which was thresholded and 
overlaid in pseudo-color onto the average normalized T1 image. As the dynamic analysis of 
rsFC data across sessions and time points is intrinsically multi-factorial, a full factorial data 
model (3-way ANOVA) was used to produced data-cells in such a way to separate (and account 
for) the variance associated with all three possible factors (session, treatment, scan) and their 
interactions and to minimize the error variance in the contrast. However, all main and interaction 
effects from the full model were considered not of interest. In fact, the session factor captures 
any changes between first and second sessions regardless of these being GHB or placebo 
sessions, the treatment factor captures any changes between GHB and placebo sessions 
including those occurring at baseline time points and the scan factor captures any change 
between time points regardless of these occurring in GHB or placebo sessions. Moreover, any 
interaction among these factors would require the calculation of additional post hoc contrasts to 
facilitate the interpretation of any detected effects. Therefore, to reduce the burden of multiple 
comparisons and simplify the interpretation of the effects of interest (GHB-related changes from 
baseline to challenge [+ 34 min] vs. placebo-related changes from baseline to challenge) we 
only considered the cells GHB-baseline, GHB-challenge, placebo-baseline and placebo-
challenge to calculate the main contrast of interest, albeit properly accounting for all confounding 
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effects in the statistics and anyway reporting the full time-course of the rsFC responses for any 
region exhibiting statistically significant effects. 
To protect against false positives and correct for multiple comparisons, only statistically 
significant regional effects were displayed for compact clusters surviving the joint application of a 
voxel- and a cluster-level threshold, which were chosen using a non-parametric randomization 
approach based on Monte Carlo simulations. Namely, an arbitrary (uncorrected) threshold 
(p<0.005) was initially applied to all voxels; then, a minimum cluster size was set in such a way 
that an average of 5% false positive clusters were counted in 10000 randomly generated images 
to which the same thresholds were applied. However, due to possible concerns on the multiple 
comparisons problem as addressed with cluster-level correction (Eklund et al., 2016), a stricter 
uncorrected threshold of p<0.001 has been applied. To match the level of "smoothness" 
between the calculated and the simulated images, the resulting images were spatially filtered 
with the same gaussian kernel applied to the original rsFC images. For Monte Carlo simulations, 
a BrainVoyager QX plugin was used, implementing a 3D extension of the procedure described in 
(Forman et al., 1995) for multiple comparison correction. In the course of this procedure, the 
smoothness for the images was estimated as the full-width-at-half-maximum of the gaussian 
kernel using the 3D extension of the formula in (Forman et al., 1995). 
 
2.6.4 Region-of-interest based Analysis of Functional Connectivity Maps 
For regions identified in the above analysis, mean regional functional connectivity z-values were 
extracted for each scan, session and subject, and used for ROI based correlation analyses with 
subjective VAS measures of sedation and stimulation. One subject was excluded from these 
analyses due to missing VAS values in one of the sessions. 
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Correlation analyses entailed with calculating the regional functional connectivity z value and 
VAS changes (∆_Z and ∆_VAS) between challenge (t=+34 min) and baseline (t=-20 min) time 
points, and then linearly regressing ∆_Z values vs. ∆_VAS in each separate treatment (GHB or 
placebo). Given the small sample (and the noisy ∆_Z measures), to make the correlation 
findings less susceptible to outliers in the data, we used a robust (weighted) linear regression 
model and anyway reported a box plot of ∆_Z measures (with medians, quartiles and outliers) 
next to each scatter plot (with trend lines). Moreover, in order to dissociate between mechanisms 
of sedation and stimulation, a robust (weighted) multivariate regression analysis was performed 
in Matlab® (The Mathworks, Inc., Natick, MA, United States, www.mathworks.com) with the 
function robustfit and default settings (iteratively reweighted least squares with a bisquare 
weighting function), where the changes in VAS scores of sedation (∆_VAS sedation) and 
stimulation (∆_VAS stimulation) were included as two independent predictors for the FC 
changes (∆_Z FC), and the statistical significance of each linear trend is reported (for baseline 
and challenge [+ 34 min] time points). 
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3. RESULTS 
3.1 Subjective Ratings 
In drug × time (2×6) ANOVAs with session as between-subject factor, the general drug effect, 
sedation, and stimulation VAS ratings showed significant time (F(5,25)=11.1–17.7, p<.001), drug 
(F(1,29)=19.2–29.7, p<.001) and drug × time interactions (F(5,25)=5.1–10.4, p<.01-.001). The 
factor session (GHB-first vs. placebo-first) was not significant (F(1,29)=0.00–0.06, p=.81–.95). 
Paired t-test (Bonferroni-corrected) revealed significant GHB effects for all three VAS measures 
in most of the time points after drug administration (Figure 1). 
 
- Figure 1 - 
 
3.2 Neuroimaging 
3.2.1 Motion and Dimensionality Analysis of rsFC time-series 
Prior to nuisance and motion regression, the mean FD was estimated from each time-series and 
statistically assessed across experimental conditions (time points and sessions). For each 
condition, the mean FD was far below the critical threshold of 0.5 mm indicated by Power et al. 
(2012) for data set exclusion (see supplementary figure 3). However, it was significantly higher 
at challenge (t=+34 min), post-task 1 (t=+59 min) and post-task 2 (t=+79 min) time points 
compared to baseline (t=-20 min) (1 sample paired t-test, p<0.05), and was also slightly higher in 
GHB, compared to placebo, sessions, albeit only at post-task 1 (t=+59 min) (1 sample paired t-
test, p=0.03), a time point which was not selected for the main contrast of interest in second-
level analyses. Although the mean FD was not significantly different between GHB and placebo 
sessions at baseline (t=-20 min) and challenge (t=+34 min) time points, this measure was 
considered as covariate of no interest for the second-level analysis and was regressed out from 
the series of functional connectivity z-maps (as resulting from either ICA or seed-based 
analyses) entering the ANOVA data model (and the contrast calculation). 
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After nuisance and motion regression, MDL was used to analytically estimate the number of ICA 
components in each data set. In average, MDL yielded 31±4 (mean ± SD) components per data 
set which analytically justifies the empirical choice of extracting 30 components per scan (see 
also, e. g. (Shirer et al., 2015). 
 
3.2.2 ICA-based Analysis of Resting-state Networks 
We performed the sogICA on all baseline scans and, following Menon (Menon, 2011, 2015), 
selected the components corresponding to the DMN, SN, CEN, and VN. As often reported in the 
literature, the CEN was found as two lateralized networks (right CEN and left CEN) (Figure 2). 
Starting from the maps, we created the network masks for extracting the homologue network 
best-fitting ICA components from each data set (i.e. from each subject, at each time point) and 
examined the direct GHB effects (GHB vs. placebo) between challenge (+ 34 min) and baseline 
time points, both within the network (via voxel-wise analysis) and between the networks (via 
correlation analysis). The inter-network connectivity analysis was restricted to the networks 
included in the Menon model as the VN served only as a control network, where no drug effects 
are expected. 
When comparing challenge (t=+34 min) vs. baseline (t=-20 min) conditions, no GHB vs. placebo 
differential effects were found significant within the DMN, the CEN and the VN. Instead, when 
comparing challenge (t=+34 min) vs. baseline (t=-20 min) conditions, the differential effects of 
GHB vs. placebo were statistically significant (p<.05 cluster-level corrected, p<.001, 
uncorrected) in a region located in the dmPFC (Figure 3). Notably, the location of increased 
connectivity in the SN coincides with the a priori definition of dorsal nexus that we used in 
previous resting-state fMRI papers (Bosch et al., 2013, Scheidegger et al., 2012) and that, 
therefore, we also used here for the seed-based analysis (Figure 4). Moreover, under GHB, but 
not under placebo, the correlation between local increases in SN component scores (challenge 
vs. baseline) and local changes in cerebral blood flow (challenge vs. baseline) from 
20 
 
corresponding arterial spin labeling scans acquired in the same experiments from the same 
subjects (see (Bosch et al., 2017a) for details) in dmPFC/dorsal nexus is highly statistically 
significant (robust linear regression, p=0.0005) (Supplementary figure 4). 
Using the ICA component time-courses, the functional connectivity between any two networks 
(among the DMN, the right and left CEN and the SN) in two time points (baseline, challenge) 
were also estimated (inter-network connectivity). From this analysis, a statistically significant 
increase of the inter-network connectivity between the SN and the DMN was found at challenge 
(t=+34 min) vs. baseline (t=-20 min) under GHB treatment (1 sample paired t-test: p=0.029 after 
Bonferroni correction for all pairs of networks and time points). This was not the case for placebo 
treatment (p>0.05). At challenge (t=+34 min), the inter-network connectivity between SN and 
DMN was also significantly higher for GHB vs. placebo sessions (1 sample paired t-test: 
p=0.048 after Bonferroni correction for all pairs of networks and time points). However, when 
mean connectivity regression was applied to each individual inter-network connectivity matrix, 
none of the inter-network connections remained statistically significant in the group analysis. 
Finally, to show where, in the frequency domain, the original source of the observed functional 
connectivity increases occurs, the average spectral features of the SN component time-courses 
were extracted and are reported in supplementary figure 5. Considering the average of all 
smoothed magnitude FFT spectra of the SN component time-courses from all scans (grouped by 
condition and time point), these spectral plots show that, compared to placebo, at challenge 
(t=+34 min), GHB significantly increases the SN spectral power only within the frequency band 
0.01Hz-0.04Hz (p<0.05), and significantly decreases the SN spectral power only at frequencies 
above 0.08Hz (p<0.05). At baseline, there are no significant differences in the spectral features 
between GHB and placebo sessions. 
  
 
- Figures 2-4- 
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3.2.3 Seed-based Analysis of dorsal nexus connectivity 
The seed-based analysis was performed using the PCC (to depict the DMN) as well as the 
dorsal nexus, as seeds, according to previous studies (Bosch et al., 2013, Scheidegger et al., 
2012). However, compared to ICA-based analyses, the approach to control for the effects of 
motion on a within-subject level was even more stringent, as, besides the regression of WM and 
CSF nuisance signals and 24 motion parameters, volume censoring was also applied. More 
specifically, prior to nuisance and motion regression, volume censoring was also applied to all 
volumes exhibiting an FD above 0.2 mm as well as to the two volumes preceding and following 
such volumes in the time-series. Nonetheless, for all data sets, the number of motion-free 
volumes was significantly above 80% and there was no significant difference between GHB and 
placebo sessions at baseline and challenge time points. 
We found no statistically significant differences in PCC-rsFC between GHB and placebo, which 
is in-line with the ICA results. In contrast, dorsal nexus-rsFC connectivity was increased to the 
right anterior insula and the right middle frontal gyrus (MFG) from baseline (t=-20 min) to 
challenge (t=+34 min), under GHB vs. placebo (p<.05 cluster-level corrected, p<.001 
uncorrected) (Figure 5). Crucially, these two clusters of differential connectivity respectively fall 
within the SN and right CEN networks (Figure 6). Moreover, at a looser cluster-forming 
threshold of p<.005 uncorrected (p<.05 cluster-level corrected), we also found that the region in 
the right anterior insula which showed increased dorsal nexus connectivity after GHB challenge 
partly overlaps with one of the two regions with increased regional cerebral blood flow under 
GHB vs. placebo (Figure 7) (Bosch et al., 2017a). 
 
- Figures 5-7- 
 
3.2.4 Region-of-interest based Analysis of Functional Connectivity Maps 
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All three regions for which we detected significant changes from baseline to challenge (+ 34 min) 
after GHB vs. placebo were considered regions of interest and further investigated for possible 
correlations between the changes in the subjective effects (∆_VAS = VAS1 vs. VAS2) from 
baseline to challenge and the corresponding changes in the functional connectivity values 
(∆_FC) from baseline to challenge. Using stimulation and sedation subjective ratings as two 
independent predictors for the regional SN component scores in dorsal nexus, a robust 
multivariate regression analysis highlighted a statistically significant (p<.05) correlation between 
∆_FC and ∆_VAS for sedation, at +34 min (p=0.013), but not for stimulation (p>0.05), under 
GHB, but not under placebo (p>0.05) (see supplementary figure 6). Similar trends were 
observed for the right anterior insula (GHB, sedation: p=0.062, stimulation: p>0.1; placebo: 
p>0.1) and the right middle frontal gyrus (GHB, sedation: p=0.058, stimulation: p>0.1; placebo: 
p>0.1), when considering the regions resulting from the seed-based analysis (see 
supplementary figures 7 and 8). 
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4. DISCUSSION 
As expected, 35 mg/kg p.o. GHB elicited mixed sedative-stimulant effects in healthy males on 
the subjective level (Bosch et al., 2015). At the neuronal level, GHB increased the inter-network 
connectivity between SN and DMN, and the within-network connectivity of the SN to an area in 
the dmPFC, which highly overlapped with the previously studied dorsal nexus hub region. 
Reciprocally, the seed-based connectivity from the dorsal nexus was increased to the right 
anterior insula, which belongs to the SN, and to the right MFG, which belongs to the right CEN. 
In contrast, within-network functional connectivity of DMN and CEN networks remained 
unchanged, and, when using both sedation and stimulation subjective ratings, only sedation 
significantly predicted the increased SN connectivity to the dorsal nexus. 
In general, the dynamic analysis of ICA spatial maps of rsFC time-series across sessions and 
time points is intrinsically multi-factorial and may thus reflect both changes in neural activity or 
connectivity and non-neural phenomena. In similar cases, more complex generative models (as 
an alternative to factorial models) might in principle enable the separate estimation of true neural 
connectivity effects and other effects on the hemodynamic compartment (Tsvetanov et al., 
2016). In our case, however, the spectral plots clearly show that, even if the spatial layout of the 
SN component partly overlaps with vascular territories, the observed GHB-related increases in 
SN component time-course activity occur mainly within the so-called slow-5 and slow-4 
frequency bands of rsFC activity (Zuo et al., 2010), whereas the reductions in the same activity 
are confined to higher frequencies (>0.08 Hz). As slow-5 and slow-4 rsFC oscillations are 
primarily originated (and detected) within the gray matter, whereas non-neural signals, such as 
respiratory and (aliased) cardiac signals that originate from the vascular territories, fall in the 
range of the so-called slow-3 and slow-2 frequency bands (Zuo et al., 2010), this observation 
clearly suggests that the here reported SN increases most likely reflect changes in true neural 
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signals rather (or more) than vascular signals1. This evidence is further corroborated by the 
highly significant correlation found between local SN component activity increases and rCBF 
increases in the dorsal nexus region, the latter being measured from fully independent data sets 
acquired from the same subjects in the same sessions and time points with the arterial spin 
labeling technique (Bosch et al., 2017a). 
Notwithstanding the above considerations, the inter-network connectivity results (for which we 
unfortunately did not have the rCBF counterpart) should still be interpreted with caution. In fact, 
when mean connectivity regression of the within-subject connectivity matrices was applied to 
each data set prior to group statistics (according to Geerligs et al., 2017), these findings ceased 
to result statistically significant. Thus, on the one hand, albeit unlikely, we cannot completely 
exclude that such inter-network connectivity effects are related to the different vascular health of 
our subjects, which, in turn, might have determined a different global response of rsFC 
correlations after GHB (vs. placebo) at challenge (+ 34 min) vs. baseline. On the other hand, it 
should be also noted that when only six connections (from four networks) are considered, even a 
single connection substantially changing between conditions or time points may result in a 
substantial change in the overall mean connectivity in most individuals, causing the group effect 
to disappear in all connections when mean connectivity regression is applied. Indeed, the mean 
connectivity regression was shown by Geerligs et al. (2017) for cases with much bigger 
connectivity matrices, implicitly suggesting that this type of correction could be particularly 
appropriate and effective for connectome-wide analyses where, e. g., more than 100 regions are 
tested for possible connectivity changes.           
Vigilance reduction, induced either by GABAergic sedative drugs such as zolpidem (Licata et al., 
2013), midazolam (Greicius et al., 2008, Kiviniemi et al., 2005), and alcohol (Esposito et al., 
2010, Khalili-Mahani et al., 2012), or by non-pharmacological interventions such as sleep 
                                                          
1
 It might be also worth noting that because ICA component time-courses are intrinsically normalized to 
unit variance/power any increase in this power within a limited frequency band is necessarily 
compensated by an equal reduction in a different frequency band. 
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deprivation (Bosch et al., 2013, De Havas et al., 2012, Samann et al., 2010) or falling asleep 
(Horovitz et al., 2009, Larson-Prior et al., 2009) have been consistently associated with reduced 
DMN within-network connectivity and increased connectivity of the DMN with the SN and the 
CEN. Comparably, high vigilance states, induced by stimulants (Cera et al., 2014, Esposito et 
al., 2013, Farr et al., 2014, Kline et al., 2016, Mueller et al., 2014, Sripada et al., 2013) or non-
pharmacological interventions (Wang et al., 2016) have been also associated with increased and 
reduced connectivity of the DMN, pointing towards the necessity of a more detailed analysis of 
these phenomena. Interestingly, in our healthy subjects GHB induced sedation as well as 
stimulation, without altering rsFC within the DMN. On the other hand, SN-DMN-rsFC was 
increased under influence of the drug. While latter observation replicates earlier findings, the 
unchanged rsFC within DMN at first glance surprising, as GABAergic stimulation usually 
paralleled by vigilance reduction was consistently found to reduce intrinsic DMN-rsFC (see 
above). However, this discrepancy might be well explained by the finding that GHB unlike other 
GABAergic drugs consistently exerts a mixed sedative-stimulant pattern (Abanades et al., 2006, 
Bosch et al., 2015), in which the stimulant part might be induced by indirect dopaminergic 
enhancement via disinhibition of the VTA and NAcc (Bosch and Seifritz, 2016). As sedative 
drugs tend to reduce, whereas stimulants rather increase intrinsic DMN-rsFC, the co-occurrence 
of sedative and stimulant effects of GHB seem to counterbalance each other on the DMN level, 
resulting in no significant differences compared to placebo.  
Regarding the SN, GHB not only increased its between-network connectivity to the DMN, but 
also increased its intrinsic rsFC to a region in the dmPFC that highly overlapped with our a priori 
selected dorsal nexus-seed, which is discussed as a biomarker for antidepressant treatment 
response (Bosch et al., 2013, McCabe et al., 2011, Scheidegger et al., 2012, Sheline et al., 
2010). Increased rsFC within the SN was also reported under light sedation with midazolam in 
healthy subjects (Liang et al., 2015). In our subjects, GHB activates the SN, a network which 
provides the detection of biologically relevant internal and external stimuli to guide adaptive 
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behavior, and which is anchored in the anterior insula and the dorsal ACC as well as in 
subcortical structures such as the ventral striatum/Nacc and the VTA (Menon and Uddin, 2010, 
Menon, 2011, 2015). Interestingly, dorsal nexus-rsFC was reciprocally increased to the right 
anterior insula, and this region highly overlapped with the insular rCBF-increase that was 
previously demonstrated under GHB (Bosch et al., 2017a), both strengthening the assumption of 
a functional coupling of the SN and the dorsal nexus under the influence of the drug.  
One key function of the SN is switching between DMN and CEN on the base of incoming 
sensory and limbic stimuli (Menon and Uddin, 2010, Menon, 2011, 2015). In our healthy 
subjects, the switching between the SN and DMN was directly (and globally) strengthened by 
GHB treatment, as suggested by the significantly increased inter-network connectivity between 
the SN and DMN after GHB (vs. placebo) challenge (+ 34 min) and vs. baseline. In other 
studies, SN-DMN-rsFC was positively associated with cognitive control (Jilka et al., 2014) and 
creative thinking (Beaty et al., 2015), while it was reduced in patients with major depressive 
disorder (Sacchet et al., 2016, Yang et al., 2016). 
In contrast, the switching between the SN and CEN was not directly (and globally) strengthened 
under GHB, as the inter-network connectivity between the SN and the CENs was not 
significantly increased. Actually, the switching between the SN and the CEN appeared indirectly 
(and locally) strengthened via the dorsal nexus hub, as this node showed increased connectivity 
to both the SN (via the anterior insula) and the CEN (via the MFG), albeit at the used statistical 
threshold, these effects were only significant for the right hemisphere (i.e. right anterior insula 
and right MFG). This however was also in line with previous ASL and rsFC results (Bosch et al., 
2017a, Bosch et al., 2017b). Thus, GHB induced a complex pattern of functional connectivity 
increase encompassing all three core neurocognitive networks of the brain: the DMN, SN, and 
CEN.  
Moreover, when both stimulation and sedation subjective ratings were jointly used as 
independent behavioral predictors for the local changes in the SN component scores in the 
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dorsal nexus region, a positive correlation was found for sedation, but not for stimulation, and 
similar trends were observed for the right anterior insula and the right middle frontal gyrus.  
In the framework of the dorsal nexus biomarker of depression hypothesis, an increase of dorsal 
nexus -rsFC to dlPFC, which also belongs to the CEN, was interpreted as one of the 
antidepressive mechanisms of sleep deprivation (Bosch et al., 2013). Although GHB was shown 
to enhance mood in healthy subjects (Bosch et al., 2015), clinical evidence regarding GHB in 
depression is scarce (Bosch et al., 2012, Bosch and Seifritz, 2016, Mamelak, 2009). Therefore, 
no valid conclusion in respect of the relationship of GHB-induced dorsal nexus rsFC and 
depression can be drawn. However, in our study dorsal nexus connectivity effectively served as 
a biomarker for a subjective drug effect, in this case sedation, underlining its role as a central 
hub region and its usefulness in neuropsychopharmacological research. 
 
Additional evidences for a complex neuronal equilibrium between stimulating and sedating 
effects of GHB derive from a recent study, where we assessed exact low resolution 
electromagnetic tomography of resting-state high-density electroencephalographic (EEG) 
recordings under influence of the drug in healthy humans (von Rotz et al., 2017). Our findings 
confirmed an earlier described “paradoxical EEG-behavioral dissociation” characterized by 
electrophysiological states that resemble loss of consciousness (mirrored in the emergence of 
low frequency oscillations) in awake and partially stimulated subjects. In these subjects, GHB led 
to the emergence of theta oscillations in the PCC (the same area we used as seed to assess 
DMN connectivity). Theta oscillations usually occur during sleep and would be expected to be 
paralleled by reduced rsFC within DMN (Samann et al., 2011). Contrary and intriguingly, theta 
oscillations occurred together with an increased intrinsic DMN-rsFC, which was positively 
correlated with GHB plasma values. Here, the seemingly paradoxical GHB effect of co-
occurrence of electrophysiological sleep signs and alert wakefulness was explained by the 
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counterbalance of PCC-generated theta oscillations and strengthened connectivity within the 
DMN. 
Taken together, subjective, fMRI, and EEG data emerging from studies on the effects of GHB 
show a coherent and unique neuropsychopharmacological signature. It consists of a subjective 
pattern of mixed stimulation and sedation, stable/increased DMN- and increased SN-, and dorsal 
nexus-, and indirectly also CEN-rsFC, as well as PCC-generated theta oscillation emergence. 
These alterations are most likely generated by a concert of primary GABAergic and secondary 
dopaminergic mechanisms, pharmacologically positioning GHB in between sedative drugs such 
as benzodiazepines and z-substances, and stimulants such as methylphenidate and modafinil. 
This “pluripotency” including mood and hedonia enhancement shown previously (Bosch et al., 
2015, 2017a,b), makes GHB a unique and interesting research tool and experimental 
therapeutic in neuropsychiatric disorders, e.g., depression, but also a dangerous drug of abuse. 
The present study bears a number of limitations: our sample size was moderate and limited to 
male subjects, as gender-dependent GHB effects on sexual arousal were tested in the fMRI part 
of the study (Bosch et al., 2017b). Moreover, we only used a single dose of GHB in this first 
attempt due to feasibility reasons. Further studies should therefore employ increased sample 
sizes, male and female subjects, and dose variations to confirm and extend the here reported 
results. 
 
5. CONCLUSIONS 
In summary, GHB exerts a mixed sedative-stimulant subjective effect, which is paralleled by 
increased intrinsic SN-rsFC to the dorsal nexus, and reciprocally increased dorsal nexus-rsFC to 
the SN (right anterior insula), as well as a CEN area, the right MFG. Moreover, rsFC between 
SN and DMN was also increased. Subjective sedation was mediated by increased SN-rsFC to 
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the dorsal nexus. Consequently, the subjective state induced by GHB is accompanied by a 
complex pattern of increased functional connectivity encompassing all three core neurocognitive 
networks of the brain (DMN, SN, CEN), while increased SN-dorsal nexus-rsFC was 
demonstrated to be a potential signature of the sedative component of the drug effect. 
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Figure Legends 
Fig. 1: Effects on visual analogue scale (VAS) scores of GHB vs. placebo for general drug 
effect, sedation, and stimulation. ***p<.001, **p<.01, *p<.05 (Bonferroni-corrected). 
Fig. 2: Main effects of the group components corresponding to the networks of interest as 
obtained from the group-level from independent component analysis of all baseline 
scans. 
Fig. 3: Contrast of GHB vs. placebo effects on salience network from independent component 
analysis including time-course of effects, all FWE-corrected and including time-course of 
resting-state functional connectivity changes, ***p<.005. 
Fig. 4: Overlap of region of salience network connectivity increase under GHB (turquoise) and a 
priori defined dorsal nexus (brown).   
Fig. 5: Dorsal nexus resting-state functional connectivity changes GHB vs. placebo: A) Dorsal 
nexus seed location, B) whole-brain dorsal nexus connectivity map, C) right anterior 
insula, D) right middle frontal gyrus, all FWE-corrected and including time-course of 
resting-state functional connectivity changes, ***p<.001, **p<.005. MFG: middle frontal 
gyrus. 
Fig. 6: A) Right anterior insula (peak of dorsal nexus connectivity) vs. salience network map, B) 
Right middle frontal gyrus (peak of dorsal nexus connectivity) vs. right central executive 
network map. 
Fig. 7: Overlap of GHB-induced increase of dorsal nexus connectivity to right anterior insula 
(orange) and regional cerebral blood flow increase to right anterior insula after GHB 
(from Bosch et al. 2017a). 
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Supplementary Figure 1 
 
Session procedure. VAS: visual analog scale, RST: resting‐state, ASL: arterial spin labeling, GHB: gamma‐
hydroxybutyrate. 
 
Supplementary Figure 2 
 
  
Visual analog scale, items “general drug effect”, “stimulation, and “sedation” (German version). 
Supplementary Figure 3 
 
 
Mean frame‐wise displacement [mm] (left) and percentage of motion‐free volumes (right) across scans and 
conditions (GHB vs PLACEBO). 
   
Supplementary Figure 4 
 
Box (left, center) and scatter (right) plots of the local increases in salience network component scores 
(challenge vs. baseline) and in cerebral blood flow [ml/100g/min] (challenge vs. baseline) from corresponding 
arterial spin labeling scans (see Bosch et al., 2017a for details) in dmPFC/dorsal nexus. Trend lines and 
statistical significances of the correlations (robust multivariate regression) are shown on the scatter plot.  
   
Supplementary Figure 5 
 
Average of all smoothed magnitude FFT spectra of the salience network component time‐courses 
from all challenge and baseline scans (grouped by condition and time point) (GHB vs. placebo). Black 
asterisks are placed at frequency bins where the difference between conditions is statistically 
significant (paired t‐test, p<=0.05). 
 
   
Supplementary Figure 6 
 
Left: Box plot of the changes (challenge vs. baseline) in the regional salience network component scores (∆_FC) 
in dorsal nexus (DN). Right: Stimulation and sedation subjective ratings as two independent predictors for the 
regional salience network component scores in dorsal nexus (robust multivariate regression analysis): 
statistically significant (p<.05) correlation between ∆_FC and ∆_VAS for sedation at +34 min (p=0.013), but not 
for stimulation (p>0.05), under GHB, but not under placebo (p>0.05). Trend lines and statistical significances of 
the correlations (robust multivariate regression) are shown on the scatter plot of ∆_FC and ∆_VAS measures.  
 
   
Supplementary Figure 7 
 
 
Left: Box plot of the changes (challenge vs. baseline) in the regional functional connectivity scores (∆_FC) from 
the dorsal nexus (DN) seed in the right anterior insula. Right: Stimulation and sedation subjective ratings as 
two independent predictors for the regional functional connectivity scores in the right anterior insula (robust 
multivariate regression analysis): trend correlations between ∆_FC and ∆_VAS are more evident for sedation at 
+34 min (p=0.062), than for stimulation (p>0.1), under GHB, but not under placebo (p>0.1). Trend lines and 
statistical significances of these correlations (robust multivariate regression) are shown on the scatter plot of 
∆_FC and ∆_VAS measures. 
   
Supplementary Figure 8 
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Left: Box plot of the changes (challenge vs. baseline) in the regional functional connectivity scores (∆_FC) from 
the dorsal nexus (DN) seed in the right middle frontal gyrus (MFG). Right: Stimulation and sedation subjective 
ratings as two independent predictors for the regional functional connectivity scores in the right MFG (robust 
multivariate regression analysis): trend correlations between ∆_FC and ∆_VAS are more evident for sedation at 
+34 min (p=0.058), than for stimulation (p>0.1), under GHB, but not under placebo (p>0.1). Trend lines and 
statistical significances of these correlations (robust multivariate regression) are shown on the scatter plot of 
∆_FC and ∆_VAS measures. 
   
Supplementary Figure 9 
 
Whole‐brain dorsal nexus resting state functional connectivity map, A) placebo, B) GHB at 34 min. p<.05 (cluster 
corrected).  
